KR102000301B1 - 산화방지성 염증 조절제로서의 피라졸릴 및 피리미디닐 트리사이클릭 엔온 - Google Patents
산화방지성 염증 조절제로서의 피라졸릴 및 피리미디닐 트리사이클릭 엔온 Download PDFInfo
- Publication number
- KR102000301B1 KR102000301B1 KR1020137018672A KR20137018672A KR102000301B1 KR 102000301 B1 KR102000301 B1 KR 102000301B1 KR 1020137018672 A KR1020137018672 A KR 1020137018672A KR 20137018672 A KR20137018672 A KR 20137018672A KR 102000301 B1 KR102000301 B1 KR 102000301B1
- Authority
- KR
- South Korea
- Prior art keywords
- delete delete
- compound
- amino
- aralkyl
- heteroaryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- HXPDCERWPYPLDF-MBSDFSHPSA-N CC(C)([C@H]1[C@](C)(C=C2C#N)c3nc(-c(cc4)ccc4OC)ncc3CC1)C2=O Chemical compound CC(C)([C@H]1[C@](C)(C=C2C#N)c3nc(-c(cc4)ccc4OC)ncc3CC1)C2=O HXPDCERWPYPLDF-MBSDFSHPSA-N 0.000 description 2
- QDWZCECIFIQMAP-JTSKRJEESA-N CC(C)([C@H]1[C@](C)(C=C2C#N)c3nc(-c(cccc4)c4Cl)ncc3CC1)C2=O Chemical compound CC(C)([C@H]1[C@](C)(C=C2C#N)c3nc(-c(cccc4)c4Cl)ncc3CC1)C2=O QDWZCECIFIQMAP-JTSKRJEESA-N 0.000 description 2
- RYRINMFTHDRFHC-YWZLYKJASA-N CC(C)([C@H]1[C@](C)(C=C2C#N)c3nc(-c4c[s]c(C)n4)ncc3CC1)C2=O Chemical compound CC(C)([C@H]1[C@](C)(C=C2C#N)c3nc(-c4c[s]c(C)n4)ncc3CC1)C2=O RYRINMFTHDRFHC-YWZLYKJASA-N 0.000 description 2
- AWNKVNUSWYTISD-KKSFZXQISA-N CC(C)([C@H]1[C@](C)(C=C2C#N)c3nc(-c4ccccn4)ncc3CC1)C2=O Chemical compound CC(C)([C@H]1[C@](C)(C=C2C#N)c3nc(-c4ccccn4)ncc3CC1)C2=O AWNKVNUSWYTISD-KKSFZXQISA-N 0.000 description 2
- OLWQYPBWOYIRPS-KKSFZXQISA-N CC(C)([C@H]1[C@](C)(C=C2C#N)c3nc(-c4cccnc4)ncc3CC1)C2=O Chemical compound CC(C)([C@H]1[C@](C)(C=C2C#N)c3nc(-c4cccnc4)ncc3CC1)C2=O OLWQYPBWOYIRPS-KKSFZXQISA-N 0.000 description 2
- DSPSILXGNFXEFS-KKSFZXQISA-N CC(C)([C@H]1[C@](C)(C=C2C#N)c3nc(-c4ccncc4)ncc3CC1)C2=O Chemical compound CC(C)([C@H]1[C@](C)(C=C2C#N)c3nc(-c4ccncc4)ncc3CC1)C2=O DSPSILXGNFXEFS-KKSFZXQISA-N 0.000 description 2
- JEHLWXHYYYMHEG-UGSOOPFHSA-N CC(C)([C@H]1[C@](C)(C=C2C#N)c3nc(C)nc(OC)c3CC1)C2=O Chemical compound CC(C)([C@H]1[C@](C)(C=C2C#N)c3nc(C)nc(OC)c3CC1)C2=O JEHLWXHYYYMHEG-UGSOOPFHSA-N 0.000 description 2
- YXDUNEXWSDVKDG-JXBWDGJFSA-N CCOC(c1nc(OC)c(CC[C@@H]([C@H](C)C2=O)[C@]3(C)C=C2C#N)c3n1)=O Chemical compound CCOC(c1nc(OC)c(CC[C@@H]([C@H](C)C2=O)[C@]3(C)C=C2C#N)c3n1)=O YXDUNEXWSDVKDG-JXBWDGJFSA-N 0.000 description 2
- NAIZMISNLZATQF-IGMHASDESA-N CCOc1c(CC[C@@H]([C@H](C)C2=O)[C@]3(C)C=C2C#N)c3nc(-c2ccccc2)n1 Chemical compound CCOc1c(CC[C@@H]([C@H](C)C2=O)[C@]3(C)C=C2C#N)c3nc(-c2ccccc2)n1 NAIZMISNLZATQF-IGMHASDESA-N 0.000 description 2
- ULLKIYYOLGCJPJ-SPEDKVCISA-N CC[C@@H]([C@H]1[C@](C)(C=C2C#N)c3nc(-c4ccccc4)ncc3CC1)C2=O Chemical compound CC[C@@H]([C@H]1[C@](C)(C=C2C#N)c3nc(-c4ccccc4)ncc3CC1)C2=O ULLKIYYOLGCJPJ-SPEDKVCISA-N 0.000 description 2
- GZYXTYURMDJKEM-DYALPIRYSA-N C[C@@H]([C@H]1[C@](C)(C=C2C#N)c3nc(-c(cccc4)c4OC)nc(OC)c3CC1)C2=O Chemical compound C[C@@H]([C@H]1[C@](C)(C=C2C#N)c3nc(-c(cccc4)c4OC)nc(OC)c3CC1)C2=O GZYXTYURMDJKEM-DYALPIRYSA-N 0.000 description 2
- VIKXYSXMLNENBO-SAZGQGMLSA-N C[C@@H]([C@H]1[C@](C)(C=C2C#N)c3nc(-c4cccnc4)nc(OC)c3CC1)C2=O Chemical compound C[C@@H]([C@H]1[C@](C)(C=C2C#N)c3nc(-c4cccnc4)nc(OC)c3CC1)C2=O VIKXYSXMLNENBO-SAZGQGMLSA-N 0.000 description 2
- OEIFLGGCKNMJLG-SAZGQGMLSA-N C[C@@H]([C@H]1[C@](C)(C=C2C#N)c3nc(-c4ccncc4)nc(OC)c3CC1)C2=O Chemical compound C[C@@H]([C@H]1[C@](C)(C=C2C#N)c3nc(-c4ccncc4)nc(OC)c3CC1)C2=O OEIFLGGCKNMJLG-SAZGQGMLSA-N 0.000 description 2
- KSQTVKKTLNTPHO-YHYSRRTLSA-N C[C@@H]([C@H]1[C@](C)(C=C2C#N)c3nc(C)nc(OC)c3CC1)C2=O Chemical compound C[C@@H]([C@H]1[C@](C)(C=C2C#N)c3nc(C)nc(OC)c3CC1)C2=O KSQTVKKTLNTPHO-YHYSRRTLSA-N 0.000 description 2
- UBSFPQASQDJAJC-OVSFNBESSA-N C[C@@H]([C@H]1[C@](C)(C=C2C#N)c3nc(OC)nc(OC)c3CC1)C2=O Chemical compound C[C@@H]([C@H]1[C@](C)(C=C2C#N)c3nc(OC)nc(OC)c3CC1)C2=O UBSFPQASQDJAJC-OVSFNBESSA-N 0.000 description 2
- 0 C[C@](C1CCC2C(*)(*)C3=O)(*2(C)I=C3C#N)N(*)C[C@@]1(*)N* Chemical compound C[C@](C1CCC2C(*)(*)C3=O)(*2(C)I=C3C#N)N(*)C[C@@]1(*)N* 0.000 description 2
- GAUNYGXOFWHERA-XOBRGWDASA-N CC(C)(C)c1ncc(CC[C@@H](C(C)(C)C2=O)[C@]3(C)C=C2C#N)c3n1 Chemical compound CC(C)(C)c1ncc(CC[C@@H](C(C)(C)C2=O)[C@]3(C)C=C2C#N)c3n1 GAUNYGXOFWHERA-XOBRGWDASA-N 0.000 description 1
- SODUKBRVKIBHTO-ZBEGNZNMSA-N CC(C)([C@H](CC1)[C@](C)(C=C2C#N)C(N3)=C1C=NC3=O)C2=O Chemical compound CC(C)([C@H](CC1)[C@](C)(C=C2C#N)C(N3)=C1C=NC3=O)C2=O SODUKBRVKIBHTO-ZBEGNZNMSA-N 0.000 description 1
- CKZFMTFBRKGPLN-UGSOOPFHSA-N CC(C)([C@H](CC1)[C@](C)(C=C2C#N)C(N=C(C)N3C)=C1C3=O)C2=O Chemical compound CC(C)([C@H](CC1)[C@](C)(C=C2C#N)C(N=C(C)N3C)=C1C3=O)C2=O CKZFMTFBRKGPLN-UGSOOPFHSA-N 0.000 description 1
- GADIZBIEZMICTC-CYFREDJKSA-N CC(C)([C@H](CC1)[C@](C)(C=C2C#N)c([n]3nc4)c1cnc3c4-c1ccccc1)C2=O Chemical compound CC(C)([C@H](CC1)[C@](C)(C=C2C#N)c([n]3nc4)c1cnc3c4-c1ccccc1)C2=O GADIZBIEZMICTC-CYFREDJKSA-N 0.000 description 1
- DAPGMCNRPGEUQG-UGSOOPFHSA-N CC(C)([C@H](CC1)[C@](C)(C=C2C#N)c([n]3nc4)c1cnc3c4Br)C2=O Chemical compound CC(C)([C@H](CC1)[C@](C)(C=C2C#N)c([n]3nc4)c1cnc3c4Br)C2=O DAPGMCNRPGEUQG-UGSOOPFHSA-N 0.000 description 1
- IYEGHUHOUCGFRL-UGSOOPFHSA-N CC(C)([C@H](CC1)[C@](C)(C=C2C#N)c3c1cnc1ccn[n]31)C2=O Chemical compound CC(C)([C@H](CC1)[C@](C)(C=C2C#N)c3c1cnc1ccn[n]31)C2=O IYEGHUHOUCGFRL-UGSOOPFHSA-N 0.000 description 1
- DTLQLCAQWCYXHV-SBUREZEXSA-N CC(C)([C@H](CCc1c2-c3n[n](Cc4ccccc4)nn3)[C@](C)(C=C3C#N)c1n[n]2I)C3=O Chemical compound CC(C)([C@H](CCc1c2-c3n[n](Cc4ccccc4)nn3)[C@](C)(C=C3C#N)c1n[n]2I)C3=O DTLQLCAQWCYXHV-SBUREZEXSA-N 0.000 description 1
- VNZIDCWKMCKDPR-UGSOOPFHSA-N CC(C)([C@H](CCc1c[n]2nc3)[C@](C)(C=C4C#N)c1nc2c3Br)C4=O Chemical compound CC(C)([C@H](CCc1c[n]2nc3)[C@](C)(C=C4C#N)c1nc2c3Br)C4=O VNZIDCWKMCKDPR-UGSOOPFHSA-N 0.000 description 1
- OMYJUFHDGMWDAC-DJJJIMSYSA-N CC(C)([C@H]1[C@](C)(C=C2C#N)c3n[n](C)c(-c4n[o]c(C)n4)c3CC1)C2=O Chemical compound CC(C)([C@H]1[C@](C)(C=C2C#N)c3n[n](C)c(-c4n[o]c(C)n4)c3CC1)C2=O OMYJUFHDGMWDAC-DJJJIMSYSA-N 0.000 description 1
- XDZUASMUXWWOKN-DJJJIMSYSA-N CC(C)([C@H]1[C@](C)(C=C2C#N)c3n[n](C)c(-c4nc(C)n[o]4)c3CC1)C2=O Chemical compound CC(C)([C@H]1[C@](C)(C=C2C#N)c3n[n](C)c(-c4nc(C)n[o]4)c3CC1)C2=O XDZUASMUXWWOKN-DJJJIMSYSA-N 0.000 description 1
- LKTBHVAFXNABAS-DJJJIMSYSA-N CC(C)([C@H]1[C@](C)(C=C2C#N)c3n[n](C)c(-c4nnc(C)[o]4)c3CC1)C2=O Chemical compound CC(C)([C@H]1[C@](C)(C=C2C#N)c3n[n](C)c(-c4nnc(C)[o]4)c3CC1)C2=O LKTBHVAFXNABAS-DJJJIMSYSA-N 0.000 description 1
- UFAGWWHWFLIBNV-JTSKRJEESA-N CC(C)([C@H]1[C@](C)(C=C2C#N)c3nc(-c(cc4)ccc4Cl)ncc3CC1)C2=O Chemical compound CC(C)([C@H]1[C@](C)(C=C2C#N)c3nc(-c(cc4)ccc4Cl)ncc3CC1)C2=O UFAGWWHWFLIBNV-JTSKRJEESA-N 0.000 description 1
- QUWICLMIJMOEKY-MBSDFSHPSA-N CC(C)([C@H]1[C@](C)(C=C2C#N)c3nc(-c4cccc(C)c4)ncc3CC1)C2=O Chemical compound CC(C)([C@H]1[C@](C)(C=C2C#N)c3nc(-c4cccc(C)c4)ncc3CC1)C2=O QUWICLMIJMOEKY-MBSDFSHPSA-N 0.000 description 1
- PKDHAODPAVTFMM-JTSKRJEESA-N CC(C)([C@H]1[C@](C)(C=C2C#N)c3nc(-c4ccccc4)ncc3CC1)C2=O Chemical compound CC(C)([C@H]1[C@](C)(C=C2C#N)c3nc(-c4ccccc4)ncc3CC1)C2=O PKDHAODPAVTFMM-JTSKRJEESA-N 0.000 description 1
- MMEGIHMTGOMJLI-ZBEGNZNMSA-N CC(C)([C@H]1[C@](C)(C=C2C#N)c3nc(C(F)(F)F)ncc3CC1)C2=O Chemical compound CC(C)([C@H]1[C@](C)(C=C2C#N)c3nc(C(F)(F)F)ncc3CC1)C2=O MMEGIHMTGOMJLI-ZBEGNZNMSA-N 0.000 description 1
- LCYXAVCWHYEDLV-MBSDFSHPSA-N CC(C)([C@H]1[C@](C)(C=C2C#N)c3nc(C)nc(-c4ccccc4)c3CC1)C2=O Chemical compound CC(C)([C@H]1[C@](C)(C=C2C#N)c3nc(C)nc(-c4ccccc4)c3CC1)C2=O LCYXAVCWHYEDLV-MBSDFSHPSA-N 0.000 description 1
- NPLGRLQBGCBHPB-GUYCJALGSA-N CC(C)([C@H]1[C@](C)(C=C2C#N)c3nc(C)ncc3CC1)C2=O Chemical compound CC(C)([C@H]1[C@](C)(C=C2C#N)c3nc(C)ncc3CC1)C2=O NPLGRLQBGCBHPB-GUYCJALGSA-N 0.000 description 1
- SRWPGDSMRWPRND-SJCJKPOMSA-N CC(C)([C@H]1[C@](C)(C=C2C#N)c3nc(OC)ncc3CC1)C2=O Chemical compound CC(C)([C@H]1[C@](C)(C=C2C#N)c3nc(OC)ncc3CC1)C2=O SRWPGDSMRWPRND-SJCJKPOMSA-N 0.000 description 1
- WPYAPEMOPCDZSU-LRDDRELGSA-N CC(C)([C@H]1[C@](C)(C=C2C#N)c3ncncc3CC1)C2=O Chemical compound CC(C)([C@H]1[C@](C)(C=C2C#N)c3ncncc3CC1)C2=O WPYAPEMOPCDZSU-LRDDRELGSA-N 0.000 description 1
- JQIUOUMJXAEARL-SYNWPBDVSA-N CC(C)([C@H]1[C@](C)([C@H]2O[C@]22C#N)c3n[n](CCC(C)([C@H]4[C@](C)(C=C5C(F)(F)F)c6n[n](C)c(-c7ccccc7)c6CC4)C5=O)c(-c4ccccc4)c3CC1)C2=O Chemical compound CC(C)([C@H]1[C@](C)([C@H]2O[C@]22C#N)c3n[n](CCC(C)([C@H]4[C@](C)(C=C5C(F)(F)F)c6n[n](C)c(-c7ccccc7)c6CC4)C5=O)c(-c4ccccc4)c3CC1)C2=O JQIUOUMJXAEARL-SYNWPBDVSA-N 0.000 description 1
- WDVOGUBCDZCVAD-BTYIYWSLSA-N CC(C)[n]1nc(-c2c(CC[C@@H](C(C)(C)C3=O)[C@]4(C)C=C3C#N)c4n[n]2C)nc1 Chemical compound CC(C)[n]1nc(-c2c(CC[C@@H](C(C)(C)C3=O)[C@]4(C)C=C3C#N)c4n[n]2C)nc1 WDVOGUBCDZCVAD-BTYIYWSLSA-N 0.000 description 1
- PFCQTQVHUXVOOI-XOBRGWDASA-N CC(C)[n]1nnc(-c2c(CC[C@@H](C(C)(C)C3=O)[C@]4(C)C=C3C#N)c4n[n]2C)n1 Chemical compound CC(C)[n]1nnc(-c2c(CC[C@@H](C(C)(C)C3=O)[C@]4(C)C=C3C#N)c4n[n]2C)n1 PFCQTQVHUXVOOI-XOBRGWDASA-N 0.000 description 1
- BQEQOJBHMLVDDC-LIRRHRJNSA-N CC(C)c1ncc(CC[C@@H](C(C)(C)C2=O)[C@]3(C)C=C2C#N)c3n1 Chemical compound CC(C)c1ncc(CC[C@@H](C(C)(C)C2=O)[C@]3(C)C=C2C#N)c3n1 BQEQOJBHMLVDDC-LIRRHRJNSA-N 0.000 description 1
- SGGZYJPXEPCKCV-APXLUKDGSA-N CCCCNc1c(CC[C@@H]([C@H](C)C2=O)[C@]3(C)C=C2C#N)c3nc(C)n1 Chemical compound CCCCNc1c(CC[C@@H]([C@H](C)C2=O)[C@]3(C)C=C2C#N)c3nc(C)n1 SGGZYJPXEPCKCV-APXLUKDGSA-N 0.000 description 1
- AUMCEBDPKRNGNN-IGMHASDESA-N CCOC([n]1nc([C@](C)([C@@H](CC2)[C@H](C)C3=O)C=C3C#N)c2c1-c1ccccc1)=O Chemical compound CCOC([n]1nc([C@](C)([C@@H](CC2)[C@H](C)C3=O)C=C3C#N)c2c1-c1ccccc1)=O AUMCEBDPKRNGNN-IGMHASDESA-N 0.000 description 1
- LJSYSOMJPNEPOX-QOKQMOMRSA-N CCOc1c(CC[C@@H]([C@H](C)C2=O)[C@]3(C)C=C2C#N)c3nc(C(C)(C)C)n1 Chemical compound CCOc1c(CC[C@@H]([C@H](C)C2=O)[C@]3(C)C=C2C#N)c3nc(C(C)(C)C)n1 LJSYSOMJPNEPOX-QOKQMOMRSA-N 0.000 description 1
- WCUZTRLZJWTMQU-KCJDHBRGSA-N CCOc1c(CC[C@@H]([C@H](C)C2=O)[C@]3(C)C=C2C#N)c3nc(C)n1 Chemical compound CCOc1c(CC[C@@H]([C@H](C)C2=O)[C@]3(C)C=C2C#N)c3nc(C)n1 WCUZTRLZJWTMQU-KCJDHBRGSA-N 0.000 description 1
- UGFLIRGABUGULC-KLRAXDNASA-N CCOc1c(CC[C@@H]([C@H](C)C2=O)[C@]3(C)C=C2C#N)c3nc(OCC)n1 Chemical compound CCOc1c(CC[C@@H]([C@H](C)C2=O)[C@]3(C)C=C2C#N)c3nc(OCC)n1 UGFLIRGABUGULC-KLRAXDNASA-N 0.000 description 1
- UOAJJRIQRUFABR-SRMJIJMDSA-N C[C@@H]([C@H](CC1)[C@](C)(C=C2C#N)C(N=C(c3ccccc3)N3C)=C1C3=O)C2=O Chemical compound C[C@@H]([C@H](CC1)[C@](C)(C=C2C#N)C(N=C(c3ccccc3)N3C)=C1C3=O)C2=O UOAJJRIQRUFABR-SRMJIJMDSA-N 0.000 description 1
- OSPHQFXSRTZTRC-APXLUKDGSA-N C[C@@H]([C@H]1[C@](C)(C=C2C#N)c3n[nH]c(-c4ccccc4)c3CC1)C2=O Chemical compound C[C@@H]([C@H]1[C@](C)(C=C2C#N)c3n[nH]c(-c4ccccc4)c3CC1)C2=O OSPHQFXSRTZTRC-APXLUKDGSA-N 0.000 description 1
- VBGIUVZGVHCVAH-VNMLXUOPSA-N C[C@@H]([C@H]1[C@](C)(C=C2C#N)c3n[n](C(C)=O)c(-c4ccccc4)c3CC1)C2=O Chemical compound C[C@@H]([C@H]1[C@](C)(C=C2C#N)c3n[n](C(C)=O)c(-c4ccccc4)c3CC1)C2=O VBGIUVZGVHCVAH-VNMLXUOPSA-N 0.000 description 1
- VWLILTVKTKQXKU-SAZGQGMLSA-N C[C@@H]([C@H]1[C@](C)(C=C2C#N)c3n[n](C)c(-c4ccccc4F)c3CC1)C2=O Chemical compound C[C@@H]([C@H]1[C@](C)(C=C2C#N)c3n[n](C)c(-c4ccccc4F)c3CC1)C2=O VWLILTVKTKQXKU-SAZGQGMLSA-N 0.000 description 1
- WWHAVJDFAILAME-LCMPSIMXSA-N C[C@@H]([C@H]1[C@](C)(C=C2C#N)c3n[n](C)c(-c4ccccn4)c3CC1)C2=O Chemical compound C[C@@H]([C@H]1[C@](C)(C=C2C#N)c3n[n](C)c(-c4ccccn4)c3CC1)C2=O WWHAVJDFAILAME-LCMPSIMXSA-N 0.000 description 1
- RERSJJNGGFWBML-YUPPNZSBSA-N C[C@@H]([C@H]1[C@](C)(C=C2C#N)c3n[n](C)c(-c4cccnc4)c3CC1)C2O Chemical compound C[C@@H]([C@H]1[C@](C)(C=C2C#N)c3n[n](C)c(-c4cccnc4)c3CC1)C2O RERSJJNGGFWBML-YUPPNZSBSA-N 0.000 description 1
- DOSAYVZYQUDVJQ-LLJZQGTPSA-N C[C@@H]([C@H]1[C@](C)(C=C2C#N)c3n[n](C)c(-c4cncnc4)c3CC1)C2=O Chemical compound C[C@@H]([C@H]1[C@](C)(C=C2C#N)c3n[n](C)c(-c4cncnc4)c3CC1)C2=O DOSAYVZYQUDVJQ-LLJZQGTPSA-N 0.000 description 1
- UYMHYZMFMMBWJE-GOJSPZCYSA-N C[C@@H]([C@H]1[C@](C)(C=C2C#N)c3n[n](C)c(-c4nc(C)n[o]4)c3CC1)C2=O Chemical compound C[C@@H]([C@H]1[C@](C)(C=C2C#N)c3n[n](C)c(-c4nc(C)n[o]4)c3CC1)C2=O UYMHYZMFMMBWJE-GOJSPZCYSA-N 0.000 description 1
- ZXGBKEALIWVHML-GOJSPZCYSA-N C[C@@H]([C@H]1[C@](C)(C=C2C#N)c3n[n](C)c(-c4nnc(C)[o]4)c3CC1)C2=O Chemical compound C[C@@H]([C@H]1[C@](C)(C=C2C#N)c3n[n](C)c(-c4nnc(C)[o]4)c3CC1)C2=O ZXGBKEALIWVHML-GOJSPZCYSA-N 0.000 description 1
- ULDQZIIZHCTFLP-HCYDYPBKSA-N C[C@@H]([C@H]1[C@](C)(C=C2C#N)c3n[n](C)c(C#N)c3CC1)C2=O Chemical compound C[C@@H]([C@H]1[C@](C)(C=C2C#N)c3n[n](C)c(C#N)c3CC1)C2=O ULDQZIIZHCTFLP-HCYDYPBKSA-N 0.000 description 1
- XYVQACGXPFQNNT-SRMJIJMDSA-N C[C@@H]([C@H]1[C@](C)(C=C2C#N)c3nc(-c4ccccc4)nc(OC)c3CC1)C2=O Chemical compound C[C@@H]([C@H]1[C@](C)(C=C2C#N)c3nc(-c4ccccc4)nc(OC)c3CC1)C2=O XYVQACGXPFQNNT-SRMJIJMDSA-N 0.000 description 1
- XGEGUFBFJQYKOH-GTXQTCRKSA-N C[C@@H]([C@H]1[C@](C)(C=C2C#N)c3nc(-c4ccccc4)ncc3CC1)C2=O Chemical compound C[C@@H]([C@H]1[C@](C)(C=C2C#N)c3nc(-c4ccccc4)ncc3CC1)C2=O XGEGUFBFJQYKOH-GTXQTCRKSA-N 0.000 description 1
- RXUDJODRSOLSLN-ORBZYBPHSA-N C[C@@H]([C@H]1[C@](C)(C=C2C#N)c3nc(-c4cncnc4)nc(OC)c3CC1)C2=O Chemical compound C[C@@H]([C@H]1[C@](C)(C=C2C#N)c3nc(-c4cncnc4)nc(OC)c3CC1)C2=O RXUDJODRSOLSLN-ORBZYBPHSA-N 0.000 description 1
- IBXFMXQWBHTXMV-YZIJFISFSA-N C[C@@H]([C@H]1[C@](C)(C=C2C#N)c3nc(C(C)(C)C)nc(OC)c3CC1)C2=O Chemical compound C[C@@H]([C@H]1[C@](C)(C=C2C#N)c3nc(C(C)(C)C)nc(OC)c3CC1)C2=O IBXFMXQWBHTXMV-YZIJFISFSA-N 0.000 description 1
- RGYSOBNRKSEAQI-KCJDHBRGSA-N C[C@@H]([C@H]1[C@](C)(C=C2C#N)c3nc(C)nc(N(C)C)c3CC1)C2=O Chemical compound C[C@@H]([C@H]1[C@](C)(C=C2C#N)c3nc(C)nc(N(C)C)c3CC1)C2=O RGYSOBNRKSEAQI-KCJDHBRGSA-N 0.000 description 1
- HCWNJVBPXUIXHM-APXLUKDGSA-N C[C@@H]([C@H]1[C@](C)(C=C2C#N)c3nc(C)nc(N4CCOCC4)c3CC1)C2=O Chemical compound C[C@@H]([C@H]1[C@](C)(C=C2C#N)c3nc(C)nc(N4CCOCC4)c3CC1)C2=O HCWNJVBPXUIXHM-APXLUKDGSA-N 0.000 description 1
- CZHBXISOUBWIGX-YHYSRRTLSA-N C[C@@H]([C@H]1[C@](C)(C=C2C#N)c3nc(C)nc(NC)c3CC1)C2=O Chemical compound C[C@@H]([C@H]1[C@](C)(C=C2C#N)c3nc(C)nc(NC)c3CC1)C2=O CZHBXISOUBWIGX-YHYSRRTLSA-N 0.000 description 1
- JAZYMAIUWXWJGQ-LUFJJVMOSA-N C[C@@H]([C@H]1[C@](C)(C=C2C#N)c3nc(C)ncc3CC1)C2=O Chemical compound C[C@@H]([C@H]1[C@](C)(C=C2C#N)c3nc(C)ncc3CC1)C2=O JAZYMAIUWXWJGQ-LUFJJVMOSA-N 0.000 description 1
- PTDROBRKKAXCKF-KDDHCUDTSA-N C[C@@H]([C@H]1[C@](C)(C=C2C#N)c3nc(C4CC4)nc(OC)c3CC1)C2=O Chemical compound C[C@@H]([C@H]1[C@](C)(C=C2C#N)c3nc(C4CC4)nc(OC)c3CC1)C2=O PTDROBRKKAXCKF-KDDHCUDTSA-N 0.000 description 1
- OKSWMGXWTVAOFV-HCYDYPBKSA-N C[C@@H]([C@H]1[C@](C)(C=C2C#N)c3ncnc(OC)c3CC1)C2=O Chemical compound C[C@@H]([C@H]1[C@](C)(C=C2C#N)c3ncnc(OC)c3CC1)C2=O OKSWMGXWTVAOFV-HCYDYPBKSA-N 0.000 description 1
- JWXAAANSIOXOFQ-LCMPSIMXSA-N C[C@@H]([C@H]1[C@](C)(C=C2C(F)(F)F)c3n[n](C)c(-c4ccccc4)c3CC1)C2=O Chemical compound C[C@@H]([C@H]1[C@](C)(C=C2C(F)(F)F)c3n[n](C)c(-c4ccccc4)c3CC1)C2=O JWXAAANSIOXOFQ-LCMPSIMXSA-N 0.000 description 1
- JZMPCDIHZBFYSU-XOYNXPIASA-N C[C@@H]([C@H]1[C@](C)([C@H]2O[C@]22C#N)c3n[n](C)c(-c4ccccc4)c3CC1)C2=O Chemical compound C[C@@H]([C@H]1[C@](C)([C@H]2O[C@]22C#N)c3n[n](C)c(-c4ccccc4)c3CC1)C2=O JZMPCDIHZBFYSU-XOYNXPIASA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/45—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C255/47—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of rings being part of condensed ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201061424601P | 2010-12-17 | 2010-12-17 | |
| US61/424,601 | 2010-12-17 | ||
| PCT/US2011/065897 WO2012083306A2 (en) | 2010-12-17 | 2011-12-19 | Pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20130130784A KR20130130784A (ko) | 2013-12-02 |
| KR102000301B1 true KR102000301B1 (ko) | 2019-07-15 |
Family
ID=45470714
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020137018672A Active KR102000301B1 (ko) | 2010-12-17 | 2011-12-19 | 산화방지성 염증 조절제로서의 피라졸릴 및 피리미디닐 트리사이클릭 엔온 |
Country Status (32)
| Country | Link |
|---|---|
| US (6) | US8513436B2 (https=) |
| EP (1) | EP2651902B1 (https=) |
| JP (1) | JP5857068B2 (https=) |
| KR (1) | KR102000301B1 (https=) |
| CN (1) | CN103596929B (https=) |
| AR (1) | AR084353A1 (https=) |
| AU (1) | AU2011343466B2 (https=) |
| BR (1) | BR112013015241B1 (https=) |
| CA (1) | CA2822071C (https=) |
| CL (1) | CL2013001754A1 (https=) |
| CO (1) | CO6910185A2 (https=) |
| CY (1) | CY1120032T1 (https=) |
| DK (1) | DK2651902T3 (https=) |
| EA (1) | EA025568B1 (https=) |
| ES (1) | ES2653717T3 (https=) |
| HR (1) | HRP20171859T1 (https=) |
| HU (1) | HUE038046T2 (https=) |
| IL (1) | IL226923A (https=) |
| LT (1) | LT2651902T (https=) |
| ME (1) | ME02973B (https=) |
| MX (1) | MX2013006902A (https=) |
| NO (1) | NO2651902T3 (https=) |
| NZ (1) | NZ612788A (https=) |
| PL (1) | PL2651902T3 (https=) |
| PT (1) | PT2651902T (https=) |
| RS (1) | RS56795B1 (https=) |
| SG (1) | SG191181A1 (https=) |
| SI (1) | SI2651902T1 (https=) |
| SM (1) | SMT201800069T1 (https=) |
| TW (1) | TWI527788B (https=) |
| WO (1) | WO2012083306A2 (https=) |
| ZA (1) | ZA201305060B (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0907423A2 (pt) | 2008-01-11 | 2020-10-27 | Reata Pharmaceuticals, Inc. | composto triterpenoide sintético para uso em um método de melhoria da função renal em um indivíduo, e uso do referido composto |
| WO2009146218A2 (en) | 2008-04-18 | 2009-12-03 | Reata Pharmaceuticals, Inc. | Compounds including an anti-inflammatory pharmacore and methods of use |
| JP5529851B2 (ja) | 2008-04-18 | 2014-06-25 | リアタ ファーマシューティカルズ インコーポレイテッド | 抗酸化炎症モジュレーター：ｃ−１７においてアミノ改変およびその他の改変を加えたオレアノール酸誘導体 |
| CN103596929B (zh) | 2010-12-17 | 2016-10-19 | 里亚塔医药公司 | 作为抗氧化发炎调节剂的吡唑及嘧啶三环烯酮 |
| BR112013015000A2 (pt) | 2010-12-17 | 2016-08-09 | Novartis Ag | formas cristalinas de 5-cloron2-(2-isopropóxi-5-metil-4-piperidin-4-il-fenil)-n4-[2-(propano-2-sulfonil)-fenil]-pirimidina-2,4-diamina |
| TWI623548B (zh) | 2012-04-27 | 2018-05-11 | 瑞塔醫藥有限責任公司 | 齊墩果酸（ｂａｒｄｏｘｏｌｏｎｅ ｍｅｔｈｙｌ）之２，２-二氟基丙醯胺衍生物、多晶型及其使用方法 |
| WO2013188818A1 (en) | 2012-06-15 | 2013-12-19 | Reata Pharmaceuticals, Inc. | A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof |
| JP6243428B2 (ja) | 2012-09-10 | 2017-12-06 | リアタ ファーマシューティカルズ インコーポレイテッド | オレアノール酸のｃ１７−アルカンジイルおよびアルケンジイル誘導体ならびにその使用方法 |
| WO2014040073A1 (en) | 2012-09-10 | 2014-03-13 | Reata Pharmaceuticals, Inc. | C13-hydroxy derivatives of oleanolic acid and methods of use thereof |
| US9512094B2 (en) | 2012-09-10 | 2016-12-06 | Reata Pharmaceuticals, Inc. | C17-heteroaryl derivatives of oleanolic acid and methods of use thereof |
| AR096046A1 (es) | 2013-04-24 | 2015-12-02 | Abbvie Inc | Derivados de 2,2-difluoropropanamida de metil bardoxolona, formas polimórficas y métodos de uso |
| WO2015112792A1 (en) * | 2014-01-24 | 2015-07-30 | Abbvie Inc. | Aryl and arylalkyl substituted pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators |
| EP3256451B1 (en) * | 2015-02-12 | 2021-10-20 | Reata Pharmaceuticals, Inc. | Imidazolyl tricyclic enones as antioxidant inflammation modulators |
| CN110198718B (zh) | 2016-11-08 | 2023-01-10 | 里亚塔医药控股有限责任公司 | 使用甲基巴多索隆或其类似物治疗阿尔波特综合征的方法 |
| TWI831738B (zh) * | 2016-12-16 | 2024-02-11 | 美商瑞塔醫藥有限責任公司 | 用於抑制ＲＯＲγ及其他用途的嘧啶三環烯酮衍生物 |
| US11286226B2 (en) | 2017-09-21 | 2022-03-29 | Northwestern University | Polycyclic carbogenic molecules and uses thereof as anti-cancer agents |
| US11465963B2 (en) * | 2017-11-21 | 2022-10-11 | Biogen Ma Inc. | Tetrahydronaphthalene derivatives useful as Nrf2 activators |
| US11993574B2 (en) * | 2018-06-15 | 2024-05-28 | Reata Pharmaceuticals, Inc | Pyrazole and imidazole compounds for inhibition of IL-17 and RORgamma |
| US12060340B2 (en) | 2018-06-20 | 2024-08-13 | Reata Pharmaceuticals, Inc | Cysteine-dependent inverse agonists of nuclear receptors ROR-gamma/ROR-gamma-t and methods of treating diseases or disorders therewith |
| US12509438B2 (en) | 2020-01-13 | 2025-12-30 | Aptabio Therapeutics Inc. | Pyrazole derivative |
| WO2023092034A1 (en) * | 2021-11-17 | 2023-05-25 | Northwestern University | Wt-idh1 inhibition using a covalent and brain-penetrant small molecular inhibitor for ferroptosis induction in high-grade glioma |
| WO2024255851A1 (en) * | 2023-06-16 | 2024-12-19 | Nanjing Curegene Technology Co., Ltd. | Tumor-specific expression cassette and uses thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009146216A2 (en) | 2008-04-18 | 2009-12-03 | Reata Pharmaceuticals. Inc. | Antioxidant inflammation modulators: novel derivatives of oleanolic acid |
Family Cites Families (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2875201A (en) | 1957-08-28 | 1959-02-24 | Searle & Co | Dehydrotigogenone intermediates |
| US3071577A (en) * | 1959-08-13 | 1963-01-01 | Syntex Corp | Pyrimidinyl androstanes |
| US3994935A (en) * | 1975-11-24 | 1976-11-30 | E. R. Squibb & Sons, Inc. | Steroidal 16β-alkyl[16α,17-b]naphthalenes |
| NZ191586A (en) | 1978-10-10 | 1981-10-19 | Sterling Drug Inc | Cyanoketones derived from glycyrrhetinic acid and pharmaceutical compositions |
| US4395423A (en) | 1978-10-10 | 1983-07-26 | Sterling Drug Inc. | Polycyclic cyanoketones |
| CN1013672B (zh) * | 1983-10-03 | 1991-08-28 | 美国辉瑞有限公司 | 2-氨基-5-羟基-4-甲基嘧啶衍生物的制备方法 |
| US5064823A (en) | 1988-08-24 | 1991-11-12 | Research Triangle Institute | Pentacyclic triterpenoid compounds as topoisomerase inhibitors or cell differentiation inducers |
| DE4014171A1 (de) | 1990-05-03 | 1991-11-07 | Basf Ag | Cyanochinolinverbindungen |
| WO1995029912A1 (en) | 1994-04-29 | 1995-11-09 | Takeda Chemical Industries, Ltd. | Ergoline derivatives as analgesics |
| JPH08208479A (ja) * | 1994-04-29 | 1996-08-13 | Takeda Chem Ind Ltd | クラビンアルカロイド誘導体を含有する鎮痛剤 |
| KR100418202B1 (ko) * | 1994-09-09 | 2004-07-05 | 쇼죠 고야마 | 분자발현기능의억제방법 |
| US6326507B1 (en) | 1998-06-19 | 2001-12-04 | Trustees Of Dartmouth College | Therapeutic compounds and methods of use |
| US6369101B1 (en) | 1999-02-26 | 2002-04-09 | Regents Of The University Of Minnesota | Therapeutic method to treat herpes virus infection |
| DE60043400D1 (de) | 1999-05-14 | 2010-01-07 | Nereus Pharmaceuticals Inc | Interleukin-1 und Tumornekrosefaktor-alpha Modulatoren,Synthese dieser Modulatoren und Methoden zur Anwendung dieser Modulatoren |
| US6649654B1 (en) | 1999-11-23 | 2003-11-18 | The Regents Of The University Of California | Methods for identifying and using IKK inhibitors |
| US6890946B2 (en) | 1999-12-23 | 2005-05-10 | Indiana University Research And Technology Corporation | Use of parthenolide to inhibit cancer |
| ATE524170T1 (de) | 2000-02-14 | 2011-09-15 | Merck Sharp & Dohme | Östrogenrezeptor modulatoren |
| JP2001240573A (ja) | 2000-03-01 | 2001-09-04 | Meiji Seika Kaisha Ltd | トリテルペン誘導体及び肝疾患治療剤 |
| WO2002003996A1 (en) | 2000-07-12 | 2002-01-17 | RAJKUMAR, Sujatha | Use of dammarane-type tritepenoid saporins |
| US6689767B2 (en) | 2000-09-29 | 2004-02-10 | Regents Of The University Of Minnesota | Triterpenes having antibacterial activity |
| US6951847B2 (en) | 2000-09-29 | 2005-10-04 | Regents Of The University Of Minnesota | Methods of treating fungal infections using lupeol |
| AU2001294953A1 (en) | 2000-09-29 | 2002-04-08 | Regents Of The University Of Minnesota | Triterpenes having fungicidal activity against yeast |
| US6878751B1 (en) | 2000-10-19 | 2005-04-12 | Imperial College Of Science Technology And Medicine | Administration of resveratrol to treat inflammatory respiratory disorders |
| WO2002047611A2 (en) | 2000-11-28 | 2002-06-20 | Board Of Regents, The University Of Texas System | Cddo-compounds and combination therapies thereof |
| US7435755B2 (en) | 2000-11-28 | 2008-10-14 | The Trustees Of Dartmouth College | CDDO-compounds and combination therapies thereof |
| ATE375345T1 (de) * | 2000-12-28 | 2007-10-15 | Ono Pharmaceutical Co | Cyclopenta(d)pyrazolo(1,5-a)pyrimidin-verbindun als crf-rezeptor antagonist |
| AU2002308701A1 (en) | 2001-05-14 | 2002-11-25 | University Of Maryland, Baltimore | Novel alanine transaminase enzyme and methods of use |
| WO2003015761A1 (en) | 2001-08-13 | 2003-02-27 | Merck & Co., Inc. | Selective estrogen receptor modulators |
| EP1444207A2 (en) | 2001-09-19 | 2004-08-11 | Pharmacia Corporation | Substituted pyrazolyl-compounds for the treatment of inflammation |
| US6991814B2 (en) | 2001-12-13 | 2006-01-31 | Council Of Scientific And Industrial Research | Herbal medicaments for the treatment of neurocerebrovascular disorders |
| US7176237B2 (en) | 2002-01-15 | 2007-02-13 | The Trustees Of Dartmouth College | Tricyclic-bis-enone derivatives and methods of use thereof |
| CA2473799A1 (en) | 2002-01-18 | 2003-07-31 | Regents Of The University Of Minnesota | Triterpene quaternary salts as biologically active surfactants |
| WO2003081210A2 (en) | 2002-03-21 | 2003-10-02 | Sunesis Pharmaceuticals, Inc. | Identification of kinase inhibitors |
| JP2006515859A (ja) | 2002-05-13 | 2006-06-08 | トラスティーズ オブ ダートマス カレッジ | 阻害剤およびその使用法 |
| WO2004089357A2 (en) | 2003-04-02 | 2004-10-21 | Regents Of The University Of Minnesota | Anti-fungal formulation of triterpene and essential oil |
| EP1660109A4 (en) | 2003-09-02 | 2009-04-08 | Unigen Pharmaceuticals Inc | FORMULATION OF A MIXTURE OF FREE B-RING FLAVONOIDS AND FLAVANES FOR USE IN THE PREVENTION AND TREATMENT OF COGNITIVE WEAKNESSING AND AGING MEMORY DISORDERS |
| US20050208151A1 (en) | 2003-10-30 | 2005-09-22 | Entelos, Inc. | Treatment of rheumatoid arthritis with FLIP antagonists |
| US8288439B2 (en) | 2003-11-04 | 2012-10-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods and compositions for the inhibition of HIV-1 replication |
| US20060258752A1 (en) | 2004-02-12 | 2006-11-16 | Vander Jagt David L | Method and compounds for cancer treatment utilizing NFkB as a direct or ultimate target for small molecule inhibitors |
| JP2005314381A (ja) | 2004-03-30 | 2005-11-10 | Anges Mg Inc | 増殖性腎疾患の予防・治療・改善剤 |
| JP5087400B2 (ja) | 2004-09-07 | 2012-12-05 | パシフィック アロー リミテッド | アンゲロイル基を有する抗腫瘍化合物 |
| WO2006089406A1 (en) * | 2005-02-22 | 2006-08-31 | Gemin X Biotechnologies Inc. | Diterpenoid compounds, compositions thereof and their use as anti-cancer or anti-fungal agents |
| EP1863800A4 (en) | 2005-03-17 | 2011-05-04 | Harvard College | SYNTHESIS OF AVRAINVILLAMID, STEPHACIDINE B AND ANALOGUE THEREOF |
| AU2006265113A1 (en) | 2005-07-01 | 2007-01-11 | The Johns Hopkins University | Compositions and methods for the treatment or prevention of disorders relating to oxidative stress |
| DE102005041613A1 (de) | 2005-09-01 | 2007-03-08 | Ergonex Pharma Gmbh | Pharmazeutische Zusammensetzungen zur Behandlung von Karzinoid-Syndrom |
| US20070232577A1 (en) | 2006-03-23 | 2007-10-04 | Advanced Life Sciences, Inc. | Synthetic pentacyclic triterpenoids and derivatives of betulinic acid and betulin |
| US20070249561A1 (en) | 2006-04-25 | 2007-10-25 | Taylor Bradley K | Pharmacological method for treatment of neuropathic pain |
| WO2008000068A1 (en) | 2006-06-27 | 2008-01-03 | Wellington Laboratories Inc. | Method for preparing 2-iodo triterpenoid compounds |
| WO2008016095A1 (en) | 2006-08-02 | 2008-02-07 | Santen Pharmaceutical Co., Ltd. | PREVENTIVE OR REMEDY FOR KERATOCONJUNCTIVAL DISORDERS CONTAINING Nrf2 ACTIVATOR AS THE ACTIVE INGREDIENT |
| JP2008110962A (ja) | 2006-08-02 | 2008-05-15 | Santen Pharmaceut Co Ltd | Ｎｒｆ２活性化物質を有効成分として含む角結膜障害の予防または治療剤 |
| US8735411B2 (en) | 2006-10-02 | 2014-05-27 | Abbvie Inc. | Macrocyclic benzofused pyrimidine derivatives |
| WO2008063318A2 (en) | 2006-10-12 | 2008-05-29 | The Texas A & M University System And Safe Et Al | Betulinic acid, derivatives and analogs thereof and uses therefor |
| EP2094651A1 (en) | 2006-11-17 | 2009-09-02 | Trustees Of Dartmouth College | Synthesis and biological activities of new tricyclic-bis-enones (tbes) |
| US8299046B2 (en) | 2006-11-17 | 2012-10-30 | Trustees Of Dartmouth College | Synthetic triterpenoids and tricyclic-bis-enones for use in stimulating bone and cartilage growth |
| EP2680010A1 (en) | 2007-02-08 | 2014-01-01 | Biogen Idec MA Inc. | Nrf2 screening assays and related methods and compositions |
| WO2008111497A1 (ja) | 2007-03-08 | 2008-09-18 | Santen Pharmaceutical Co., Ltd. | トリテルペノイドを有効成分として含有する酸化ストレスが関連する眼疾患の予防又は治療剤 |
| WO2008136838A1 (en) | 2007-05-04 | 2008-11-13 | Trustees Of Dartmouth College | Novel amide derivatives of cddo and methods of use thereof |
| WO2009023845A2 (en) | 2007-08-15 | 2009-02-19 | The Board Of Regents Of The University Of Texas System | Combination therapy with synthetic triterpenoids and gemcitabine |
| US8088824B2 (en) | 2007-08-15 | 2012-01-03 | Reata Pharmaceuticals Inc. | Forms of CDDO methyl ester |
| WO2009058849A1 (en) | 2007-10-29 | 2009-05-07 | University Of Rochester | Use of electrophilic compounds for inducing platelet production or maintaining platelet function |
| BRPI0907423A2 (pt) | 2008-01-11 | 2020-10-27 | Reata Pharmaceuticals, Inc. | composto triterpenoide sintético para uso em um método de melhoria da função renal em um indivíduo, e uso do referido composto |
| KR101713140B1 (ko) | 2008-04-18 | 2017-03-08 | 리타 파마슈티컬스 잉크. | Ｃ-환에서 포화된 산화방지성 염증 조절제 올레아놀산 유도체 |
| MX2010011439A (es) | 2008-04-18 | 2011-01-25 | Reata Pharmaceuticals Inc | Moduladores de inflamacion antioxidantes: derivados del acido oleanolico homologacion c-17. |
| JP5529851B2 (ja) | 2008-04-18 | 2014-06-25 | リアタ ファーマシューティカルズ インコーポレイテッド | 抗酸化炎症モジュレーター：ｃ−１７においてアミノ改変およびその他の改変を加えたオレアノール酸誘導体 |
| WO2009146218A2 (en) * | 2008-04-18 | 2009-12-03 | Reata Pharmaceuticals, Inc. | Compounds including an anti-inflammatory pharmacore and methods of use |
| US8278311B2 (en) | 2008-04-28 | 2012-10-02 | Abbott Laboratories | Substituted pyrimidine derivatives |
| EP2309860B1 (en) | 2008-07-22 | 2014-01-08 | Trustees of Dartmouth College | Monocyclic cyanoenones and methods of use thereof |
| WO2010053817A1 (en) | 2008-11-04 | 2010-05-14 | Trustees Of Dartmouth College | Betulinic acid derivatives and methods of use thereof |
| SI2395979T1 (sl) | 2009-02-13 | 2017-12-29 | Reata Pharmaceuticals, Inc. | Peroralni farmacevtski sestavki, ki vsebujejo amorfni CDDO-Me, z zapoznelim sproščanjem |
| TWI481607B (zh) | 2009-12-17 | 2015-04-21 | Lundbeck & Co As H | 作為ｐｄｅ１０ａ酵素抑制劑的２－芳基咪唑衍生物 |
| DK2558105T3 (da) | 2010-04-12 | 2020-01-27 | Reata Pharmaceuticals Inc | Bardoxolonmethyl til behandling af fedme |
| CN102079772A (zh) | 2010-12-09 | 2011-06-01 | 中国药科大学 | 一类五环三萜-13,28-内酯化合物、其制备方法和用途 |
| WO2012082580A2 (en) | 2010-12-17 | 2012-06-21 | E. I. Du Pont De Nemours And Company | Fungicidal azocyclic amides |
| CN103596929B (zh) | 2010-12-17 | 2016-10-19 | 里亚塔医药公司 | 作为抗氧化发炎调节剂的吡唑及嘧啶三环烯酮 |
| US8846647B2 (en) | 2011-01-31 | 2014-09-30 | Bristol-Myers Squibb Company | C-17 and C-3 modified triterpenoids with HIV maturation inhibitory activity |
| MX348862B (es) | 2011-03-11 | 2017-07-03 | Reata Pharmaceuticals Inc | Derivados c4-monometil triterpenoides y sus metodos de uso. |
| TWI623548B (zh) | 2012-04-27 | 2018-05-11 | 瑞塔醫藥有限責任公司 | 齊墩果酸（ｂａｒｄｏｘｏｌｏｎｅ ｍｅｔｈｙｌ）之２，２-二氟基丙醯胺衍生物、多晶型及其使用方法 |
| WO2013188818A1 (en) | 2012-06-15 | 2013-12-19 | Reata Pharmaceuticals, Inc. | A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof |
| SMT201700501T1 (it) | 2012-09-10 | 2017-11-15 | Reata Pharmaceuticals Inc | Derivati c17-eteroarilici dell'acido oleanolico e metodi d'uso degli stessi |
| US9512094B2 (en) | 2012-09-10 | 2016-12-06 | Reata Pharmaceuticals, Inc. | C17-heteroaryl derivatives of oleanolic acid and methods of use thereof |
| WO2014040073A1 (en) | 2012-09-10 | 2014-03-13 | Reata Pharmaceuticals, Inc. | C13-hydroxy derivatives of oleanolic acid and methods of use thereof |
| JP6243428B2 (ja) | 2012-09-10 | 2017-12-06 | リアタ ファーマシューティカルズ インコーポレイテッド | オレアノール酸のｃ１７−アルカンジイルおよびアルケンジイル誘導体ならびにその使用方法 |
| EP4736949A2 (en) | 2013-08-23 | 2026-05-06 | Reata Pharmaceuticals Holdings, LLC | Methods of treating and preventing endothelial dysfunction using bardoxolone methyl or analogs thereof |
-
2011
- 2011-12-19 CN CN201180067948.3A patent/CN103596929B/zh active Active
- 2011-12-19 SG SG2013046198A patent/SG191181A1/en unknown
- 2011-12-19 AR ARP110104761A patent/AR084353A1/es active IP Right Grant
- 2011-12-19 NZ NZ612788A patent/NZ612788A/en unknown
- 2011-12-19 NO NO11807826A patent/NO2651902T3/no unknown
- 2011-12-19 WO PCT/US2011/065897 patent/WO2012083306A2/en not_active Ceased
- 2011-12-19 DK DK11807826.0T patent/DK2651902T3/en active
- 2011-12-19 SM SM20180069T patent/SMT201800069T1/it unknown
- 2011-12-19 CA CA2822071A patent/CA2822071C/en active Active
- 2011-12-19 LT LTEP11807826.0T patent/LT2651902T/lt unknown
- 2011-12-19 EA EA201390894A patent/EA025568B1/ru unknown
- 2011-12-19 ME MEP-2017-298A patent/ME02973B/me unknown
- 2011-12-19 PL PL11807826T patent/PL2651902T3/pl unknown
- 2011-12-19 BR BR112013015241-9A patent/BR112013015241B1/pt active IP Right Grant
- 2011-12-19 RS RS20180025A patent/RS56795B1/sr unknown
- 2011-12-19 SI SI201131385T patent/SI2651902T1/en unknown
- 2011-12-19 TW TW100147581A patent/TWI527788B/zh active
- 2011-12-19 HU HUE11807826A patent/HUE038046T2/hu unknown
- 2011-12-19 EP EP11807826.0A patent/EP2651902B1/en active Active
- 2011-12-19 HR HRP20171859TT patent/HRP20171859T1/hr unknown
- 2011-12-19 KR KR1020137018672A patent/KR102000301B1/ko active Active
- 2011-12-19 US US13/330,378 patent/US8513436B2/en active Active
- 2011-12-19 ES ES11807826.0T patent/ES2653717T3/es active Active
- 2011-12-19 AU AU2011343466A patent/AU2011343466B2/en active Active
- 2011-12-19 PT PT118078260T patent/PT2651902T/pt unknown
- 2011-12-19 JP JP2013544872A patent/JP5857068B2/ja active Active
- 2011-12-19 MX MX2013006902A patent/MX2013006902A/es unknown
-
2013
- 2013-06-13 IL IL226923A patent/IL226923A/en active IP Right Grant
- 2013-06-17 CL CL2013001754A patent/CL2013001754A1/es unknown
- 2013-07-05 ZA ZA2013/05060A patent/ZA201305060B/en unknown
- 2013-07-11 US US13/939,818 patent/US9174941B2/en active Active
- 2013-07-15 CO CO13167243A patent/CO6910185A2/es active IP Right Grant
-
2015
- 2015-10-08 US US14/877,974 patent/US9884809B2/en active Active
-
2018
- 2018-01-04 US US15/861,758 patent/US20180265455A1/en not_active Abandoned
- 2018-02-05 CY CY20181100134T patent/CY1120032T1/el unknown
-
2019
- 2019-12-03 US US16/701,585 patent/US11192852B2/en active Active
-
2021
- 2021-12-06 US US17/457,808 patent/US11814338B2/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009146216A2 (en) | 2008-04-18 | 2009-12-03 | Reata Pharmaceuticals. Inc. | Antioxidant inflammation modulators: novel derivatives of oleanolic acid |
Non-Patent Citations (2)
| Title |
|---|
| Bioorganic & Medicinal Chemistry Letters, 1997, 제7권, 제13호, 페이지 1623-1628 |
| Organic Letters, 2010, 제12권, 제3호, 페이지 508-511 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102000301B1 (ko) | 산화방지성 염증 조절제로서의 피라졸릴 및 피리미디닐 트리사이클릭 엔온 | |
| KR101956399B1 (ko) | Ｃ４모노메틸 트리터페노이드 유도체 및 그의 이용 방법 | |
| KR102237359B1 (ko) | 올레아놀산의 ｃ１７―알칸디일 및 알켄디일 유도체 및 그의 사용 방법 | |
| KR102237364B1 (ko) | 올레아놀산의 ｃ１７―헤테로아릴 유도체 및 그의 사용 방법 | |
| KR102686868B1 (ko) | 항산화 염증 조절제로서의 이미다졸릴 트리사이클릭 에논 | |
| KR20230147077A (ko) | 합성 우르솔산 유도체 및 이의 사용 방법 | |
| HK1212355B (zh) | 齐墩果酸的c17-烷二基与烯二基衍生物及其使用方法 | |
| HK1189894A (en) | C4-monomethyl triterpenoid derivatives and methods of use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20130716 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20161214 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20180409 Patent event code: PE09021S01D |
|
| E90F | Notification of reason for final refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Final Notice of Reason for Refusal Patent event date: 20181023 Patent event code: PE09021S02D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20190418 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20190709 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20190709 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration | ||
| PR1001 | Payment of annual fee |
Payment date: 20220630 Start annual number: 4 End annual number: 4 |
|
| PR1001 | Payment of annual fee |
Payment date: 20230628 Start annual number: 5 End annual number: 5 |
|
| PR1001 | Payment of annual fee |
Payment date: 20240617 Start annual number: 6 End annual number: 6 |
|
| PR1001 | Payment of annual fee |
Payment date: 20250630 Start annual number: 7 End annual number: 7 |